Catalent inks $133M deal to buy Juniper Pharmaceuticals, adding UK development services

Catalent inks $133M deal to buy Juniper Pharmaceuticals, adding UK development services

Source: 
Endpoints
snippet: 

The biopharma contract developer and manufacturer Catalent $CTLThas swooped in to buy out Juniper Pharmaceuticals $JNP for $133 million, adding their services with an eye to amping up its early drug development offerings in the UK.